LIPG endothelial lipase and breast cancer risk by subtypes

Abstract Experimental data showed that endothelial lipase (LIPG) is a crucial player in breast cancer. However, very limited data exists on the role of LIPG on the risk of breast cancer in humans. We examined the LIPG-breast cancer association within our population-based case–control study from Gali...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manuela Gago-Dominguez, Carmen M. Redondo, Manuel Calaza, Marcos Matabuena, Maria A. Bermudez, Roman Perez-Fernandez, María Torres-Español, Ángel Carracedo, J. Esteban Castelao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8a818072829441788ab4a112069dbab0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a818072829441788ab4a112069dbab0
record_format	dspace
spelling	oai:doaj.org-article:8a818072829441788ab4a112069dbab02021-12-02T16:51:04ZLIPG endothelial lipase and breast cancer risk by subtypes10.1038/s41598-021-89669-42045-2322https://doaj.org/article/8a818072829441788ab4a112069dbab02021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89669-4https://doaj.org/toc/2045-2322Abstract Experimental data showed that endothelial lipase (LIPG) is a crucial player in breast cancer. However, very limited data exists on the role of LIPG on the risk of breast cancer in humans. We examined the LIPG-breast cancer association within our population-based case–control study from Galicia, Spain, BREOGAN (BREast Oncology GAlicia Network). Plasma LIPG and/or OxLDL were measured on 114 breast cancer cases and 82 controls from our case–control study, and were included in the present study. The risk of breast cancer increased with increasing levels of LIPG (multivariable OR for the highest category (95% CI) 2.52 (1.11–5.81), P-trend = 0.037). The LIPG-breast cancer association was restricted to Pre-menopausal breast cancer (Multivariable OR for the highest LIPG category (95% CI) 4.76 (0.94–28.77), P-trend = 0.06, and 1.79 (0.61–5.29), P-trend = 0.372, for Pre-menopausal and Post-menopausal breast cancer, respectively). The LIPG-breast cancer association was restricted to Luminal A breast cancers (Multivariable OR for the highest LIPG category (95% CI) 3.70 (1.42–10.16), P-trend = 0.015, and 2.05 (0.63–7.22), P-trend = 0.311, for Luminal A and non-Luminal A breast cancers, respectively). Subset analysis only based on HER2 receptor indicated that the LIPG-breast cancer relationship was restricted to HER2-negative breast cancers (Multivariable OR for the highest LIPG category (95% CI) 4.39 (1.70–12.03), P-trend = 0.012, and 1.10 (0.28–4.32), P-trend = 0.745, for HER2-negative and HER2-positive tumors, respectively). The LIPG-breast cancer association was restricted to women with high total cholesterol levels (Multivariable OR for the highest LIPG category (95% CI) 6.30 (2.13–20.05), P-trend = 0.018, and 0.65 (0.11–3.28), P-trend = 0.786, among women with high and low cholesterol levels, respectively). The LIPG-breast cancer association was also restricted to non-postpartum breast cancer (Multivariable OR for the highest LIPG category (95% CI) 3.83 (1.37–11.39), P-trend = 0.003, and 2.35 (0.16–63.65), P-trend = 0.396, for non-postpartum and postpartum breast cancer, respectively), although we lacked precision. The LIPG-breast cancer association was more pronounced among grades II and III than grade I breast cancers (Multivariable ORs for the highest category of LIPG (95% CI) 2.73 (1.02–7.69), P-trend = 0.057, and 1.90 (0.61–6.21), P-trend = 0.170, for grades II and III, and grade I breast cancers, respectively). No association was detected for OxLDL levels and breast cancer (Multivariable OR for the highest versus the lowest category (95% CI) 1.56 (0.56–4.32), P-trend = 0.457).Manuela Gago-DominguezCarmen M. RedondoManuel CalazaMarcos MatabuenaMaria A. BermudezRoman Perez-FernandezMaría Torres-EspañolÁngel CarracedoJ. Esteban CastelaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Manuela Gago-Dominguez Carmen M. Redondo Manuel Calaza Marcos Matabuena Maria A. Bermudez Roman Perez-Fernandez María Torres-Español Ángel Carracedo J. Esteban Castelao LIPG endothelial lipase and breast cancer risk by subtypes
description	Abstract Experimental data showed that endothelial lipase (LIPG) is a crucial player in breast cancer. However, very limited data exists on the role of LIPG on the risk of breast cancer in humans. We examined the LIPG-breast cancer association within our population-based case–control study from Galicia, Spain, BREOGAN (BREast Oncology GAlicia Network). Plasma LIPG and/or OxLDL were measured on 114 breast cancer cases and 82 controls from our case–control study, and were included in the present study. The risk of breast cancer increased with increasing levels of LIPG (multivariable OR for the highest category (95% CI) 2.52 (1.11–5.81), P-trend = 0.037). The LIPG-breast cancer association was restricted to Pre-menopausal breast cancer (Multivariable OR for the highest LIPG category (95% CI) 4.76 (0.94–28.77), P-trend = 0.06, and 1.79 (0.61–5.29), P-trend = 0.372, for Pre-menopausal and Post-menopausal breast cancer, respectively). The LIPG-breast cancer association was restricted to Luminal A breast cancers (Multivariable OR for the highest LIPG category (95% CI) 3.70 (1.42–10.16), P-trend = 0.015, and 2.05 (0.63–7.22), P-trend = 0.311, for Luminal A and non-Luminal A breast cancers, respectively). Subset analysis only based on HER2 receptor indicated that the LIPG-breast cancer relationship was restricted to HER2-negative breast cancers (Multivariable OR for the highest LIPG category (95% CI) 4.39 (1.70–12.03), P-trend = 0.012, and 1.10 (0.28–4.32), P-trend = 0.745, for HER2-negative and HER2-positive tumors, respectively). The LIPG-breast cancer association was restricted to women with high total cholesterol levels (Multivariable OR for the highest LIPG category (95% CI) 6.30 (2.13–20.05), P-trend = 0.018, and 0.65 (0.11–3.28), P-trend = 0.786, among women with high and low cholesterol levels, respectively). The LIPG-breast cancer association was also restricted to non-postpartum breast cancer (Multivariable OR for the highest LIPG category (95% CI) 3.83 (1.37–11.39), P-trend = 0.003, and 2.35 (0.16–63.65), P-trend = 0.396, for non-postpartum and postpartum breast cancer, respectively), although we lacked precision. The LIPG-breast cancer association was more pronounced among grades II and III than grade I breast cancers (Multivariable ORs for the highest category of LIPG (95% CI) 2.73 (1.02–7.69), P-trend = 0.057, and 1.90 (0.61–6.21), P-trend = 0.170, for grades II and III, and grade I breast cancers, respectively). No association was detected for OxLDL levels and breast cancer (Multivariable OR for the highest versus the lowest category (95% CI) 1.56 (0.56–4.32), P-trend = 0.457).
format	article
author	Manuela Gago-Dominguez Carmen M. Redondo Manuel Calaza Marcos Matabuena Maria A. Bermudez Roman Perez-Fernandez María Torres-Español Ángel Carracedo J. Esteban Castelao
author_facet	Manuela Gago-Dominguez Carmen M. Redondo Manuel Calaza Marcos Matabuena Maria A. Bermudez Roman Perez-Fernandez María Torres-Español Ángel Carracedo J. Esteban Castelao
author_sort	Manuela Gago-Dominguez
title	LIPG endothelial lipase and breast cancer risk by subtypes
title_short	LIPG endothelial lipase and breast cancer risk by subtypes
title_full	LIPG endothelial lipase and breast cancer risk by subtypes
title_fullStr	LIPG endothelial lipase and breast cancer risk by subtypes
title_full_unstemmed	LIPG endothelial lipase and breast cancer risk by subtypes
title_sort	lipg endothelial lipase and breast cancer risk by subtypes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8a818072829441788ab4a112069dbab0
work_keys_str_mv	AT manuelagagodominguez lipgendotheliallipaseandbreastcancerriskbysubtypes AT carmenmredondo lipgendotheliallipaseandbreastcancerriskbysubtypes AT manuelcalaza lipgendotheliallipaseandbreastcancerriskbysubtypes AT marcosmatabuena lipgendotheliallipaseandbreastcancerriskbysubtypes AT mariaabermudez lipgendotheliallipaseandbreastcancerriskbysubtypes AT romanperezfernandez lipgendotheliallipaseandbreastcancerriskbysubtypes AT mariatorresespanol lipgendotheliallipaseandbreastcancerriskbysubtypes AT angelcarracedo lipgendotheliallipaseandbreastcancerriskbysubtypes AT jestebancastelao lipgendotheliallipaseandbreastcancerriskbysubtypes
_version_	1718382991304032256

LIPG endothelial lipase and breast cancer risk by subtypes

Ejemplares similares